Voyager Therapeutics, Inc. (VYGR)
$3.54+$0.08 (+2.31%) Today
Nathan D. Jorgensen - OfficerVoyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
https://www.voyagertherapeutics.comSEC filings for VYGR on EDGAR
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 9 | 270,000 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
34 Form 4 filings on record, the earliest from Oct 2, 2024, newest first. Filing history page 1 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| George A. Scangos - Director | Grant or award | Stock Option (Right to Buy) | 30,000 | $0.00 | - | |
| Catherine J. Mackey - Director | Grant or award | Stock Option (Right to Buy) | 30,000 | $0.00 | - | |
| Steven Hyman - Director | Grant or award | Stock Option (Right to Buy) | 30,000 | $0.00 | - | |
| Nancy Vitale - Director | Grant or award | Stock Option (Right to Buy) | 30,000 | $0.00 | - | |
 Michael J. Higgins - Director | Grant or award | Stock Option (Right to Buy) | 30,000 | $0.00 | - | |
 Jude Onyia - Director | Grant or award | Stock Option (Right to Buy) | 30,000 | $0.00 | - | |
| James A. Geraghty - Director | Grant or award | Stock Option (Right to Buy) | 30,000 | $0.00 | - | |
| Grace Colon - Director | Grant or award | Stock Option (Right to Buy) | 30,000 | $0.00 | - | |
| Glenn Pierce - Director | Grant or award | Stock Option (Right to Buy) | 30,000 | $0.00 | - | |
| Alfred Sandrock - Officer | Open-market sale | Common Stock | 11,511 | $3.87 | $45K | |
| Gregory L. Shiferman - Officer | Grant or award | Common Stock | 50,000 | $0.00 | - | |
| Robin Swartz - Officer | Open-market sale | Common Stock | 6,458 | $3.77 | $24K | |
| Alfred Sandrock - Officer | Open-market sale | Common Stock | 14,197 | $3.79 | $54K | |
| Nathan D. Jorgensen - Officer | Open-market sale | Common Stock | 4,668 | $3.77 | $18K | |
| Todd Alfred Carter - Officer | Open-market sale | Common Stock | 4,174 | $3.76 | $16K | |
| Robin Swartz - Officer | Open-market sale | Common Stock | 3,882 | $3.44 | $13K | |
| Todd Alfred Carter - Officer | Open-market sale | Common Stock | 3,301 | $3.44 | $11K | |
| Alfred Sandrock - Officer | Open-market sale | Common Stock | 11,732 | $3.41 | $40K | |
| Robin Swartz - Officer | Open-market sale | Common Stock | 4,569 | $3.85 | $18K | |
| Alfred Sandrock - Officer | Open-market sale | Common Stock | 12,192 | $3.78 | $46K | |
| Todd Alfred Carter - Officer | Open-market sale | Common Stock | 3,525 | $3.85 | $14K | |
| Toby Ferguson - Officer | Grant or award | Common Stock | 45,000 | $0.00 | - | |
| Toby Ferguson - Officer | Grant or award | Stock Option (Right to Buy) | 210,000 | $0.00 | - | |
| Todd Alfred Carter - Officer | Grant or award | Common Stock | 33,000 | $0.00 | - | |
| Todd Alfred Carter - Officer | Grant or award | Stock Option (Right to Buy) | 154,000 | $0.00 | - | |
| Robin Swartz - Officer | Grant or award | Common Stock | 45,000 | $0.00 | - | |
| Robin Swartz - Officer | Grant or award | Stock Option (Right to Buy) | 210,000 | $0.00 | - | |
| Alfred Sandrock - Officer | Grant or award | Common Stock | 86,250 | $0.00 | - | |
| Alfred Sandrock - Officer | Grant or award | Stock Option (Right to Buy) | 402,500 | $0.00 | - | |
| Nathan D. Jorgensen - Officer | Grant or award | Common Stock | 32,250 | $0.00 | - | |
| Nathan D. Jorgensen - Officer | Grant or award | Stock Option (Right to Buy) | 150,500 | $0.00 | - | |
| Nathan D. Jorgensen - Officer | Open-market sale | Common Stock | 7,666 | $4.78 | $37K | |
| Toby Ferguson - Officer | Open-market sale | Common Stock | 19,000 | $3.73 | $71K | |
| James A. Geraghty - Director | Grant or award | Stock Option (Right to Buy) | 24,000 | $0.00 | - | |
| George A. Scangos - Director | Grant or award | Stock Option (Right to Buy) | 24,000 | $0.00 | - |
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| - | - | - | - | View on EDGAR | |
| - | - | - | - | View on EDGAR |
Voyager Therapeutics, Inc. (VYGR) had 9 insider filings in the last 90 days, with the most recent on 2026-06-11. The full record for VYGR runs to 34 Form 4 filings, the earliest from 2024-10-02. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of VYGR were filed in the last 90 days.
No insider sales of VYGR were filed in the last 90 days. 15 sales are on record for this company.
This page tracks VYGR Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add VYGR to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
